7 research outputs found
The provincial labour force in services in Italy: estimates from the population censuses, 1871-1911
No full textThis paper provides labour force estimates in the tertiary sector for the years 1871, 1881, 1901 and 1911 for 69 Italian provinces (NUTS-3) at historical borders. Our estimates are entirely based on population censuses that are here reclassified in order to obtain consistent sectors throughout the whole period. We present figures by gender for nine broad sectors: Commerce, Communication, Credit, Public Administration, Army, Transport, Housekeeping, Worship and Other. We then discuss the main trends of the series and provide suggestions for future research
131I therapy of autonomously functioning thyroid adenoma:the results of a 40-years experience.
No full textMicronucleus and fragility test as indicators of damage response in human lymphocytes after I-131 therapy
No full textTo estimate the absorbed dose received by patients who underwent 131I therapy, a modified compartmental model of the International Commission on Radiological Protection (ICRP) was used. The activity in plasma and micronucleus (MN) frequency (MN test) were measured before and after therapy. To evaluate whether a correlation exists between lymphocytes and absorbed dose, a colorimetric test, based on the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT test), was used. Twenty patients who underwent 131I therapy were studied. Activity was measured in plasma, and isolated lymphocytes were collected to perform the MN and MTT tests. The mean MN frequency observed in unexposed patient lymphocytes was comparable with that of healthy subjects. 131I therapy induces a small increase in MN, and a good correlation with the bone marrow absorbed dose was obtained (P = 0.040). A consistent decrease in phytostimulation observed after therapy (MTT test) correlated significantly with bone marrow absorbed dose (P = 0.0085). The MTT test appears to be more reliable than the MN test for evaluating lymphocyte damage induced by 131I therapy
Death from differentiated thyroid carcinoma: Retrospective study of a 40-year investigation
No full textDifferentiated thyroid carcinoma (DTC) usually has a good prognosis, but sometimes the course of the disease results in death. The aim of the present study was to assess the effect of some variables in time to death on fatal cases in our series. A total of 83 patients with DTC who died between 1958 and 1998 from differentiated thyroid cancer were retrospectively analyzed with respect to gender, age at diagnosis, histology, percentage of 131I uptake by postoperative thyroid remnant, site of tumor growth, and its 131I uptake, metastases and time to death. Univariate analysis revealed a significantly shorter time to death in local recurrence when comparing local lymph node metastases and distant metastases even if neither show 131I uptake. Multivariate analysis revealed that age at diagnosis was the most important factor in conditioning the time to death. In conclusion, in those patients who died from DTC an older age at diagnosis and presence of local recurrence influenced the time to death independently of 311I uptake
Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases
No full textevaluated the role of first I-131-whole-body scan and of first serum thyroglobulin (Tg) measurement after surgery in the early diagnosis of metastases from differentiated thyroid carcinoma (DTC). Methods: In 269 patients with metastases from DTC, we retrospectively evaluated the results of first whole-body scan (performed 40 days after surgery with diagnostic or therapeutic I-131 dose) and in 69 of them we also evaluated the result of first Tg measurement (performed the day before the first whole-body scan) in relation to the presence, localization and type of metastases. Results: In all patients, the first whole-body scan was positive for the thyroid remnant, and in 54.3% of patients it was also positive for metastases. In the remaining 45.7% of patients, metastases were detected during the follow-up. First Tg levels were >60 ng/ml in 66.7% of patients with metastases. First whole-body scan detected metastases in 47.8% of patients with Tg values 60 ng/ml in 61.3% of patients with first whole-body scan negative for metastases. The combined results of both first whole-body scan and first Tg measurement allowed the early detection of metastases in 82.6% of patients. Whole-body scan detected distant metastases more frequently than local lymph node metastases (p < 0.01). Conclusion: In more than 80% of patients, metastases were suspected or diagnosed as early as 40 days after surgery in the presence of residual thyroid tissue by combined evaluation of results of first whole-body scan and Tg measurement
Micronucleus yield and colorimetric test as indicators of damage in patients' lymphocytes after 131I therapy
No full textTo estimate the absorbed dose received by patients who underwent 131I therapy, a modified compartmental model of the International Commission on Radiological Protection (ICRP) was used. The activity in plasma and micronucleus (MN) frequency (MN test) were measured before and after therapy. To evaluate whether a correlation exists between lymphocytes and absorbed dose, a colorimetric test, based on the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT test), was used. Methods: Twenty patients who underwent 131I therapy were studied. Activity was measured in plasma, and isolated lymphocytes were collected to perform the MN and MTT tests. Results: The mean MN frequency observed in unexposed patient lymphocytes was comparable with that of healthy subjects. 131I therapy induces a small increase in MN, and a good correlation with the bone marrow absorbed dose was obtained (P = 0.040). A consistent decrease in phytostimulation observed after therapy (MTT test) correlated significantly with bone marrow absorbed dose (P = 0.0085). Conclusion: The MTT test appears to be more reliable than the MN test for evaluating lymphocyte damage induced by 131I therapy
Low-risk Differentiated Thyroid Carcinoma - Literature Review And Management Guidelines [câncer Diferenciado Da Tiróide De Baixo Risco - Revisão Do Estado Atual Da Literatura E Proposta De Conduta]
No full textThe trend of increasing thyroid cancer has been recognized in Brazil as well as all over the world for several decades. The large use of simple and effective diagnostic tools has significantly contributed to this trend. It is estimated that small carcinomas found at surgery for benign thyroid disorders and by ultrasonography will be identified at grater frequency in the further years. Part of these tumors occurs in low-risk patients that may benefit of less aggressive management strategies. However, the characterization of low-risk patient is still confusing and we lack adequate markers to tell apart patients that may present a troublesome progression of the disease. Furthermore, the use of new follow-up methods has recently changed some guidelines. A multidisciplinary team, including basic scientists, endocrinologists, nuclear medicine physicians, thyroid surgeons and endocrine pathologists reviewed the pertinent literature and, based on their experience, propose some management guidelines for Brazilian patients with low-risk thyroid carcinomas.503550557Coeli, C.M., Brito, A.S., Barbosa, F.S., Ribeiro, M.G., Sieiro, A.P., Vaisman, M., Incidence and mortality from thyroid cancer in Brazil (2005) Arq Bras Endocrinol Metab, 49, pp. 503-509Parkin, D., Whwlan, S., Ferlay, J., Raymond, L., Young, J., Cancer incidence in five continents (1997) IARC Sci PublRenshaw, A.A., Papillary carcinoma of the thyroid ≤ 1.0 cm (2005) Cancer, 105, pp. 217-219Ito, Y., Tomoda, C., Uruno, T., Takamura, Y., Miya, A., Kobayashi, K., Papillary microcarcinoma of the thyroid: How should it be treated? (2004) World J Surg, 28, pp. 1115-1121Ito, Y., Uruno, T., Takamura, Y., Nakano, K., Takamura, Y., Miya, A., An observation trial without surgical treatment in patients with Papillary microcarcinoma of the thyroid (2003) Thyroid, 13, pp. 381-387Kovacs, G.L., Gonda, G., Vadasz, G., Ludmany, E., Uhrin, K., Gorombey, Z., Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake (2005) Thyroid, 15, pp. 152-157Matos, P.S., Ferreira, A.P.C., Ward, L.S., Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series (2006) Endocrine Pathology, , no preloCooper, D.S., Doherty, G.M., Haugen, B.R., Kloos, R.T., Lee, S.L., Mandel, S.J., Management guidelines for patients with thyroid nodules and differentiated thyroid cancer (2006) Thyroid, , E-pub ahead of printMazzaferri, E.L., Kloos, R.T., Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer (2001) J Clin Endocrinol Metab, 86, pp. 1447-1463Mazzaferri, E.L., Jhiang, S.M., Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer (1994) Am J Med, 97, pp. 418-428Schlumberger, M.J., Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status (1999) J Endocrinol Inves, 22, pp. 3-7Hay, I.D., Bergstralh, E.J., Goellner, J.R., Ebersold, J.R., Grant, C.S., Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 (1993) Surgery, 114, pp. 1050-1057Cady, B., Papillary carcinoma of the thyroid gland: Treatment based on risk group definition (1998) Surg Oncol Clin North Am, 7, pp. 633-644Shaha, A.R., Thyroid carcinoma: Implications of prognostic factors (1998) Cancer, 83, pp. 401-402Hadjieva, T., Scoring patients' risk in differentiated thyroid cancer (2001) Onkologie, 24, pp. 561-568Hundahl, S.A., Fleming, I.D., Fremgen, A.M., Menck, H.R., A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 (1998) Cancer, 83, pp. 2638-2648Hundahl, S.A., Cady, B., Cunningham, M.P., Mazzaferri, E., McKee, R.F., Rosai, J., Initial results from a prospective cohort study of 5,583 cases of thyroid carcinoma treated in the United States during 1996. US and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study (2000) Cancer, 89, pp. 202-217Kinder, B.K., Well differentiated thyroid cancer (2003) Curr Opin Oncol, 15, pp. 71-77Ronga, G., Filesi, M., Montesano, T., Melacrinis, F.F., Di Nicola, A., Ventroni, G., Death from differentiated thyroid carcinoma: Retrospective study of a 40-year investigation (2002) Cancer Biother Radiopharm, 17, pp. 507-514Shah, J.P., Loree, T.R., Dharker, D., Strong, E.W., Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: A matched-pair analysis (1993) Am J Surg, 166, pp. 331-335Wanebo, H., Coburn, M., Teates, D., Cole, B., Total thyroidectomy does not enhance disease control or survival even in high-risk patients with differentiated thyroid cancer (1998) Ann Surg, 227, pp. 912-921Chow, S.M., Law, S.C., Mendenhall, W.M., Au, S.K., Yau, S., Yuen, K.T., Follicular thyroid carcinoma: Prognostic factors and the role of radioiodine (2002) Cancer, 95, pp. 488-498Cohen, E.G., Tuttle, R.M., Kraus, D.H., Postoperative management of differentiated thyroid cancer (2003) Otolaryngol Clin North Am, 36, pp. 129-157Sawka, A.M., Thephamongkhol, K., Brouwers, M., Thabane, L., Browman, G., Gerstein, H.C., A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer (2004) J Clin Endocrinol Metab, 89, pp. 3668-3676Reynolds, J.C., Percent 131I uptake and post-therapy 131I scans: Their role in the management of thyroid cancer (1997) Thyroid, 7, pp. 281-284Pacini, F., Lippi, F., Formica, N., Elisei, R., Anelli, S., Ceccarelli, C., Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels (1987) J Nucl Med, 28, pp. 1888-1891Duren, M., Siperstein, A.E., Shen, W., Duh, Q.Y., Morita, E., Clark, O.H., Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients (1999) Surgery, 126, pp. 13-19Haugen, B.R., Pacini, F., Reiners, C., Schlumberger, M., Ladenson, P.W., Sherman, S.I., A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer (1999) J Clin Endocrinol Metab, 84, pp. 3877-3885(2003) Clinical Practice Guidelines, 1. , http://www.nccn.org/physician_gls/PDF/thyroid.pdf(2002) British Thyroid Association & Royal College of Physicians Guidelines for the Management of Thyroid Cancer in Adults, , http://www.british-thyroid-association.org/guidelines.hm, 03Schlumberger, M., Pacini, F., Wiersinga, W.M., Toft, A., Smit, J.W., Sanchez Franco, F., Follow-up and management of differentiated thyroid carcinoma: A European perspective in clinical practice (2004) Eur J Endocrinol, 151, pp. 539-548Reynolds, J.C., Percent 131I uptake and post-therapy 131I scans: Their role in the management of thyroid cancer (1997) Thyroid, 7, pp. 281-284Pujol, P., Daures, J.P., Nsakala, N., Baldet, L., Bringer, J., Jaffiol, C., Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer (1996) J Clin Endocrinol Metab, 81, pp. 4318-4323Cooper, D.S., Specker, B., Ho, M., Sperling, M., Ladenson, P.W., Ross, D.S., Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry (1998) Thyroid, 8, pp. 737-744Biondi, B., Palmieri, E.A., Fazio, S., Cosco, C., Nocera, M., Sacca, L., Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients (2000) J Clin Endocrinol Metab, 85, pp. 4701-4705Schneider, R., Reiners, C., The effect of levothyroxine therapy on bone mineral density: A systematic review of the literature (2003) Exp Clin Endocrinol Diabetes, 111, pp. 455-470Grigsby, P.W., Baglan, K., Siegel, B.A., Surveillance of patients to detect recurrent thyroid carcinoma (1999) Cancer, 85, pp. 945-951Duren, M., Siperstein, A.E., Shen, W., Duh, Q.Y., Morita, E., Clark, O.H., Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients (1999) Surgery, 126, pp. 13-19Mazzaferri, E.L., Kloos, R.T., Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? (2002) J Clin Endocrinol Metab, 87, pp. 1490-1498Toubeau, M., Touzery, C., Arveux, P., Chaplain, G., Vaillant, G., Berriolo, A., Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer (2004) J Nucl Med, 45, pp. 988-994Grigsby, P.W., Baglan, K., Siegel, B.A., Surveillance of patients to detect recurrent thyroid carcinoma (1999) Cancer, 85, pp. 945-951Franceschi, M., Kusic, Z., Franceschi, D., Lukinac, L., Roncevic, S., Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (1996) J Nucl Med, 37, pp. 446-451Frasoldati, A., Pesenti, M., Gallo, M., Caroggio, A., Salvo, D., Valcavi, R., Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma (2003) Cancer, 97, pp. 90-96Whitley, R.J., Ain, K.B., Thyroglobulin: A specific serum marker for the management of thyroid carcinoma (2004) Clin Lab Med, 24, pp. 29-47Wartofsky, L., Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin (2002) Thyroid, 12, pp. 583-590Mazzaferri, E.L., Robbins, R.J., Spencer, C.A., Braverman, L.E., Pacini, F., Wartofsky, L., A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma (2003) J Clin Endocrinol Metab, 88, pp. 1433-1441Pacini, F., Molinaro, E., Castagna, M.G., Agate, L., Elisei, R., Ceccarelli, C., Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma (2003) J Clin Endocrinol Metab, 88, pp. 3668-3673Spencer, C.A., Takeuchi, M., Kazarosyan, M., Wang, C.C., Guttler, R.B., Singer, P.A., Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma (1998) J Clin Endocrinol Metab, 83, pp. 1121-1127Elisei, R., Vivaldi, A., Agate, L., Molinaro, E., Nencetti, C., Grasso, L., Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients (2004) J Clin Endocrinol Metab, 89, pp. 33-39Jemal, A., Tiwari, R.C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Cancer statistics 2004 (2004) CA Cancer J Clin, 54, pp. 8-29Baudin, E., Do Cao, C., Cailleux, A.F., Leboulleux, S., Travagli, J.P., Schlumberger, M., Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients (2003) J Clin Endocrinol Metab, 88, pp. 1107-111
